Fishman Jay A Ltd. MI Sells 7,630 Shares of Pfizer Inc. (NYSE:PFE)

Fishman Jay A Ltd. MI cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 282,174 shares of the biopharmaceutical company’s stock after selling 7,630 shares during the quarter. Pfizer makes up approximately 0.8% of Fishman Jay A Ltd. MI’s portfolio, making the stock its 23rd biggest position. Fishman Jay A Ltd. MI’s holdings in Pfizer were worth $7,150,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Union Savings Bank boosted its stake in shares of Pfizer by 5.9% in the 1st quarter. Union Savings Bank now owns 12,124 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 680 shares during the last quarter. Nilsine Partners LLC increased its holdings in shares of Pfizer by 27.1% in the first quarter. Nilsine Partners LLC now owns 15,205 shares of the biopharmaceutical company’s stock worth $385,000 after purchasing an additional 3,245 shares during the period. Woodmont Investment Counsel LLC increased its holdings in shares of Pfizer by 6.7% in the first quarter. Woodmont Investment Counsel LLC now owns 269,981 shares of the biopharmaceutical company’s stock worth $6,841,000 after purchasing an additional 16,987 shares during the period. Monte Financial Group LLC increased its holdings in shares of Pfizer by 21.0% in the first quarter. Monte Financial Group LLC now owns 252,067 shares of the biopharmaceutical company’s stock worth $6,387,000 after purchasing an additional 43,740 shares during the period. Finally, CCG Wealth Management LLC bought a new position in shares of Pfizer in the first quarter worth $200,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of NYSE PFE opened at $23.97 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market cap of $136.27 billion, a P/E ratio of 17.37, a P/E/G ratio of 0.87 and a beta of 0.57. The firm’s fifty day moving average is $23.26 and its two-hundred day moving average is $24.90. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.82 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.18%. The ex-dividend date was Friday, May 9th. Pfizer’s dividend payout ratio is 124.64%.

Analysts Set New Price Targets

Several research firms have recently weighed in on PFE. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.